ANABIOTICASubmit a source
Peptides

GHK-Cu

A copper-binding peptide with plausible skin and wound biology but sparse controlled human evidence and no established role for injectable anti-aging use.

Emerging
Evidence rating
Evidence review

What the evidence says

GHK-Cu is a naturally occurring copper-binding tripeptide studied in wound repair, extracellular-matrix signaling, inflammation, and skin remodeling. Those mechanisms are biologically interesting, but cell and animal findings do not establish a visible anti-aging benefit in people.[1][2]

Cosmetic reviews describe small studies reporting changes in wrinkles, skin density, laxity, or collagen-related markers after topical copper-peptide products. The underlying trials are limited, often old, formulation-specific, and much less rigorous than the evidence base for sunscreen or prescription retinoids.[1][2]

No controlled evidence shows that subcutaneous GHK-Cu improves systemic aging, recovery, cognition, hair growth, or longevity. FDA materials list non-injectable GHK-Cu as under evaluation for possible compounding use after the injectable nomination was withdrawn; nomination or committee review is not drug approval.[4][3][2]

A registered clinical trial is evaluating a topical GHK-Cu formulation, illustrating that product-specific human evidence is still being built. Until adequately reported trials exist, claims should remain limited to uncertain cosmetic potential rather than treatment or rejuvenation.[5][4]

Potential benefits

  • May modestly improve selected cosmetic skin measures in formulation-specific topical use.[1][2]
  • Offers a plausible research target for wound and tissue-remodeling studies.[1]

Side effects and cautions

  • Topical products may cause irritation, allergy, or reactions to other formulation ingredients; robust long-term data are lacking.[1]
  • Injected compounded products add sterility, identity, dosing, and systemic safety risks without proven anti-aging benefit.[3]
How we scored it

Evidence breakdown

Laboratory and small cosmetic studies suggest biological activity, while product-specific clinical outcomes, long-term safety, and systemic use remain poorly established.

Clinical relevanceLow

Published human evidence is mostly small, topical, cosmetic, and focused on surrogate skin outcomes.

Study qualityLow

Reviews rely heavily on preclinical experiments and older studies with limited reporting.

Safety dataLow

Long-term topical exposure and injected compounded products lack adequate safety characterization.

References

Full source list

  1. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data

    International Journal of Molecular Sciences · 2018

  2. The human tri-peptide GHK and tissue remodeling

    Journal of Biomaterials Science, Polymer Edition · 2008

  3. Human Drug Compounding

    U.S. Food and Drug Administration · 2025

  4. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act

    U.S. Food and Drug Administration · 2026

  5. Topical GHK-Cu Gel for Acute Skin Wound Healing

    ClinicalTrials.gov · 2026